Tag: medical

ISLAMABAD, Aug. 12, 2025 /PRNewswire/ --In a pioneering step towards elevating nursing education in Pakistan, MindHYVE.ai has signed strategic Memorandum of Understanding (MoU) with...

The digital health market is experiencing robust growth, driven by increasing adoption of telemedicine, wearable devices, and AI-powered health solutions. Rising healthcare costs and...

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

With Three-Year Revenue Growth of 7260.85%, This Marks Maximus' 1st Time on the List

With Three-Year Revenue Growth of 7260.85%, This Marks Maximus' 1st Time on the List

Entered into secured credit agreement with Innoviva for $15 million maturing in 2029 Announced positive topline results from the Phase 1b/2a diSArm trial for AP-SA02 LOS...

YUPELRI® (revefenacin) net sales of $66.3 million, recognized by Viatris, increased 22% year-over-year1Pivotal Phase 3 CYPRESS study enrollment on track to complete by late...

MALVERN, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with Janus Henderson Investors, a global asset management firm, for the purchase and sale of 20,000,000 shares of common stock and warrants to purchase up to an aggregate of 20,000,000 shares of common stock at a purchase price of $1.00 per share (closing price on August 7, 2025) and accompanying warrant. The warrants have an exercise price of $1.50 per share, are exercisable immediately upon issuance, and will expire two years following the date of issuance. The warrants are callable by the Company when the VWAP of the Company’s common stock exceeds $2.50 per share for at least five of a trailing 30 trading day period. 

SACRAMENTO, Calif., Aug. 12, 2025 /PRNewswire/ -- Straine Dental Management is proud to announce it has made the prestigious Inc. 5000 list once again,...

- Seasoned global leaders have successfully supported 16 landmark nuclear projects across the UAE and China - Fermi America bringing global "Power Couple" home to...

Charity auction raises $250,000 for Children's Miracle Network Hospitals NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Children's Miracle Network Hospitals (CMN Hospitals) announced that...

Juvent joins the 2025 Inc. 5000, ranking #757 with 552% growth over 3 years, for its Micro-Impact Platform, which improves mobility, pain, and wellness.